2024-04-01 08977342 2025-01-31 08977342 2024-04-01 2025-01-31 08977342 2024-03-31 08977342 2023-04-01 2024-03-31 08977342 uk-core:WithinOneYear 2024-03-31 08977342 uk-core:WithinOneYear 2025-01-31 08977342 uk-core:AfterOneYear 2024-03-31 08977342 uk-core:AfterOneYear 2025-01-31 08977342 uk-core:ShareCapital 2025-01-31 08977342 uk-core:ShareCapital 2024-03-31 08977342 uk-core:RetainedEarningsAccumulatedLosses 2025-01-31 08977342 uk-core:RetainedEarningsAccumulatedLosses 2024-03-31 08977342 uk-bus:Director1 2024-04-01 2025-01-31 08977342 uk-core:CostValuation 2024-03-31 08977342 uk-core:CostValuation uk-core:Non-currentFinancialInstruments 2024-03-31 08977342 uk-core:CostValuation uk-core:Non-currentFinancialInstruments 2025-01-31 08977342 uk-core:CostValuation 2025-01-31 08977342 uk-core:Non-currentFinancialInstruments 2025-01-31 08977342 uk-core:Non-currentFinancialInstruments 2024-03-31 08977342 uk-core:WithinOneYear uk-core:Secured 2025-01-31 08977342 uk-core:WithinOneYear uk-core:Secured 2024-03-31 iso4217:GBP xbrli:pure 08977342 uk-bus:AuditExemptWithAccountantsReport 2024-04-01 2025-01-31 08977342 uk-bus:FRS102 2024-04-01 2025-01-31 08977342 uk-bus:FilletedAccounts 2024-04-01 2025-01-31 08977342 uk-bus:PrivateLimitedCompanyLtd 2024-04-01 2025-01-31
FK Pharma Limited
Registered Number:08977342
For the period ended 31 January 2025
England and Wales
Unaudited Financial Statements
2
For the period ended 31 January 2025
FK Pharma Limited
Contents Page
1
Statement of Financial Position
2 to 3
Notes to the Financial Statements
3
Registered Number :
08977342
As at 31 January 2025
FK Pharma Limited
Statement of Financial Position
£
£
2024
2025
Notes
Fixed assets
Financial assets
750,000
750,000
2
750,000
750,000
Current assets
Trade and other receivables
-
55,000
3
8
Cash and cash equivalents
8
55,008
8
Trade and other payables: amounts falling due within one
year
(28,051)
(23,464)
4
(28,043)
31,544
Net current assets
Total assets less current liabilities
781,544
721,957
Trade and other payables: amounts falling due after more
than one year
(694,639)
(658,669)
5
122,875
Net assets
27,318
Capital and reserves
Called up share capital
1
1
Retained earnings
122,874
27,317
122,875
27,318
Shareholders' funds
For the period ended 31 January 2025 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the period ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006
The directors acknowledge their responsibilities for:a) ensuring that the company keeps proper accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of
each financial year and of its profit or loss for each financial year in accordance with the requirements of Section
394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial
statements, so far as applicable to the company.
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Faiz Mujadad Khan Director
These financial statements were approved and authorised for issue by the Board on 29 October 2025 and were signed by:
The notes form part of these financial statements
1 of 3
4
For the period ended 31 January 2025
FK Pharma Limited
Notes to the Financial Statements
Statutory Information
FK Pharma Limited is a private limited company, limited by shares, domiciled in England and Wales, registration
number 08977342.
Registered address:
8 Woodhall Close
Bolton
Lancashire
BL2 3AZ
The presentation currency is £ sterling.
1. Accounting policies
Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A of Financial
Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the
Companies Act 2006. The financial statements have been prepared under the historical costs convention as
modified by the revaluation of certain assets.
Revenue recognition
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
2. Investments held as fixed assets
Other investments
Total
At 01 April 2024
750,000
750,000
Cost
£
£
At 31 January 2025
750,000
750,000
At 31 January 2025
Net book value
750,000
750,000
At 01 April 2024
750,000
750,000
3. Trade and other receivables
2024
2025
£
£
Other debtors
55,000
-
2 of 3
5
For the period ended 31 January 2025
FK Pharma Limited
Notes to the Financial Statements Continued
4. Trade and other payables: amounts falling due within one year
2024
2025
£
£
Bank loans and overdraft (secured)
21,500
26,827
Trade creditors
408
576
Taxation and social security
224
-
Other creditors
1,332
648
23,464
28,051
5. Trade and other payables: amounts falling due after more than one year
2024
2025
£
£
Bank loans and overdraft (secured)
557,321
571,157
Other creditors
101,348
123,482
658,669
694,639
6. Average number of persons employed
During the year the average number of employees was 0
3 of 3